Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study

Condition: Advanced Renal Cell Carcinoma (All Subtypes), Metastatic Renal Cell Carcinoma (All Subtypes)

Study Type: Observational

Clinical Trials Identifier NCT 8-digits: NCT04147143

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest



  • Age: minimum 18 Years maximum N/A
  • Gender: All

Inclusion Criteria:

  1. Written informed consent and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject
  2. Patients with advanced or metastatic renal cell carcinoma, including all subtypes
  3. Age ≥ 18 years
  4. Completion of treatment with nivolumab or nivolumab / ipilimumab combination therapy (any line of therapy) directly followed by cabozantinib treatment

Exclusion Criteria:

  1. Patients who are unable to consent because they do not understand the nature, significance and implications of the observational trial
  2. Involvement in the planning and / or conduct of the study (applies to both Ipsen staff and/or staff of sponsor and study site)

View trial on

email news signup